- Conditions
- Hyperparathyroidism
- Interventions
- Vitamin D, Four-dimensional computed tomography (4DCT)
- Drug · Device
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- 21 Years and older
- Enrollment
- 22 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2018
- U.S. locations
- 1
- States / cities
- Houston, Texas
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–24
of 6,311
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Breast Cancer
- Interventions
- Exercise Recall Patient Reported Outcomes, Health Behavior Questionnaire (HBQ)30 Patient Reported Outcomes, Functional Assessment of Cancer Therapy-General (FACT-G) Patient Reported Outcomes, Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-F) Patient Reported Outcomes, Patient Reported Outcomes PROMIS Cognitive Function (Short Form 8a), Patient Reported Outcomes Functional Assessment of Cancer-Gynecology Oncology Group-Neurotoxicity (FACT/GOG-NTX-12), Patient Reported Outcomes PROMIS, Patient Reported Outcomes FACT-Endocrine Symptoms, Patient Reported Outcomes Penn Arthralgia Aging Survey, Patient Reported Outcomes PRO-CTCAE (patient-reported CTCAE), p16 tumor suppressor gene
- Behavioral · Diagnostic Test
- Lead sponsor
- UNC Lineberger Comprehensive Cancer Center
- Other
- Eligibility
- 21 Years and older · Female only
- Enrollment
- 253 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2028
- U.S. locations
- 1
- States / cities
- Chapel Hill, North Carolina
- Conditions
- Breast Cancer
- Interventions
- trastuzumab, docetaxel and carboplatin in dose dense regimen
- Drug
- Lead sponsor
- University of Miami
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 48 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2008
- U.S. locations
- 1
- States / cities
- Miami, Florida
- Conditions
- Migraine
- Interventions
- Rimegepant, Placebo
- Drug
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 1 participant
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Hypogonadism, Primary Hypogonadism, Secondary Hypogonadism
- Interventions
- Testosterone Undecanoate 750 mg, Testosterone Undecanoate 1000 mg
- Drug
- Lead sponsor
- Endo USA Inc., a Keenova Therapeutics Company
- Industry
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 531 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2009
- U.S. locations
- 1
- States / cities
- Lexington, Massachusetts
- Conditions
- Cancer
- Interventions
- ziv-aflibercept
- Biological
- Lead sponsor
- Regeneron Pharmaceuticals
- Industry
- Eligibility
- 18 Years to 120 Years
- Enrollment
- 25 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2004
- U.S. locations
- 2
- States / cities
- New York, New York • Nashville, Tennessee
- Conditions
- Constipation, Bowel Obstruction, Fallopian Tube Cancer, Ovarian Cancer, Peritoneal Cavity Cancer
- Interventions
- Not listed
- Lead sponsor
- University of Minnesota
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 13 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2009
- U.S. locations
- 1
- States / cities
- Minneapolis, Minnesota
- Conditions
- Insomnia
- Interventions
- APD125
- Drug
- Lead sponsor
- Arena Pharmaceuticals
- Industry
- Eligibility
- 18 Years to 64 Years
- Enrollment
- 173 participants
- Timeline
- 2007
- U.S. locations
- 1
- States / cities
- San Diego, California
- Conditions
- Chronic Myeloproliferative Disorders, Graft Versus Host Disease, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Diseases
- Interventions
- mycophenolate mofetil, tacrolimus
- Drug
- Lead sponsor
- Fred Hutchinson Cancer Center
- Other
- Eligibility
- Up to 65 Years
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2004
- U.S. locations
- 1
- States / cities
- Seattle, Washington
- Conditions
- Recurrent Diffuse Hemispheric Glioma, H3 G34-Mutant, Recurrent Malignant Brain Neoplasm, Resectable Brain Neoplasm
- Interventions
- Ad-hCMV-Flt3L, Ad-hCMV-TK, Biospecimen Collection, Magnetic Resonance Imaging, Survey Administration, Tumor Resection, Valacyclovir
- Genetic · Procedure · Other + 1 more
- Lead sponsor
- University of Michigan Rogel Cancer Center
- Other
- Eligibility
- 3 Years to 39 Years
- Enrollment
- 11 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2031
- U.S. locations
- 1
- States / cities
- Ann Arbor, Michigan
- Conditions
- Fallopian Tube Endometrioid Adenocarcinoma, Fallopian Tube High Grade Serous Adenocarcinoma, Ovarian Endometrioid Adenocarcinoma, Ovarian High Grade Serous Adenocarcinoma, Primary Peritoneal Endometrioid Adenocarcinoma, Primary Peritoneal High Grade Serous Adenocarcinoma, Stage III Fallopian Tube Cancer AJCC v8, Stage III Ovarian Cancer AJCC v8, Stage III Primary Peritoneal Cancer AJCC v8, Stage IV Fallopian Tube Cancer AJCC v8, Stage IV Ovarian Cancer AJCC v8, Stage IV Primary Peritoneal Cancer AJCC v8, Unresectable Fallopian Tube Endometrioid Adenocarcinoma, Unresectable Fallopian Tube High Grade Serous Adenocarcinoma, Unresectable Ovarian Endometrioid Adenocarcinoma, Unresectable Ovarian High Grade Serous Adenocarcinoma, Unresectable Primary Peritoneal Endometrioid Adenocarcinoma, Unresectable Primary Peritoneal High Grade Serous Adenocarcinoma
- Interventions
- Biopsy Procedure, Carboplatin, Ipatasertib, Paclitaxel
- Procedure · Drug
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 25 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2027
- U.S. locations
- 8
- States / cities
- San Francisco, California • Augusta, Georgia • Cleveland, Ohio + 5 more
- Conditions
- Proteus Syndrome, PIK3CA Related Overgrowth Spectrum
- Interventions
- Not listed
- Lead sponsor
- National Human Genome Research Institute (NHGRI)
- NIH
- Eligibility
- 1 Month to 99 Years
- Enrollment
- 1,500 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 1994
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Brain Tumors, Epilepsy, Migraine, Mild Cognitive Impairment, Concussion, Multiple Sclerosis, Neuropathy, Parkinson's, Restless Legs Syndrome, Stroke
- Interventions
- Listed for each disorder below, up to three drugs per disorder (too many characters to list in this field; see Intervention Description)
- Drug
- Lead sponsor
- Endeavor Health
- Other
- Eligibility
- 18 Years to 100 Years
- Enrollment
- 3,300 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2027
- U.S. locations
- 1
- States / cities
- Evanston, Illinois
- Conditions
- Migraine Disorders
- Interventions
- Lasmiditan
- Drug
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 2,171 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2019
- U.S. locations
- 182
- States / cities
- Birmingham, Alabama • Huntsville, Alabama • Chandler, Arizona + 132 more
- Conditions
- Oropharyngeal Cancer
- Interventions
- TORS, Adjuvant Radiation Therapy
- Procedure · Radiation
- Lead sponsor
- Abramson Cancer Center at Penn Medicine
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 60 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2018
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
- Conditions
- Acute Ischemic Stroke
- Interventions
- Intravenous (IV) recombinant human tissue plasminogen activator (rtPA), Solitaire revascularization device
- Drug · Device
- Lead sponsor
- Medtronic Neurovascular Clinical Affairs
- Industry
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 196 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2015
- U.S. locations
- 1
- States / cities
- Buffalo, New York
- Conditions
- Liver Transplant, Liver Steatosis, Liver Disease, Primary Non-function, Early Allograft Dysfunction
- Interventions
- Fibroscan 402/530
- Device
- Lead sponsor
- Andres Duarte-Rojo
- Other
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 160 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2019
- U.S. locations
- 3
- States / cities
- Little Rock, Arkansas • Stanford, California • Rochester, Minnesota
- Conditions
- Large B-Cell Lymphoma With IRF4 Rearrangement, Recurrent Aggressive B-Cell Non-Hodgkin Lymphoma, Recurrent ALK-Positive Large B-Cell Lymphoma, Recurrent Diffuse Large B-Cell Lymphoma Activated B-Cell Type, Recurrent Diffuse Large B-Cell Lymphoma Associated With Chronic Inflammation, Recurrent Diffuse Large B-Cell Lymphoma Germinal Center B-Cell Type, Recurrent Diffuse Large B-Cell Lymphoma, Not Otherwise Specified, Recurrent EBV-Positive Diffuse Large B-Cell Lymphoma, Not Otherwise Specified, Recurrent Grade 3b Follicular Lymphoma, Recurrent High Grade B-Cell Lymphoma With MYC and BCL2 Rearrangements, Recurrent High Grade B-Cell Lymphoma, Not Otherwise Specified, Recurrent Intravascular Large B-Cell Lymphoma, Recurrent Primary Cutaneous Diffuse Large B-Cell Lymphoma, Leg Type, Recurrent Primary Mediastinal Large B-Cell Lymphoma, Recurrent T-Cell/Histiocyte-Rich Large B-Cell Lymphoma, Recurrent Transformed Non-Hodgkin Lymphoma, Refractory Aggressive B-Cell Non-Hodgkin Lymphoma, Refractory ALK-Positive Large B-Cell Lymphoma, Refractory Diffuse Large B-Cell Lymphoma Activated B-Cell Type, Refractory Diffuse Large B-Cell Lymphoma Associated With Chronic Inflammation, Refractory Diffuse Large B-Cell Lymphoma Germinal Center B-Cell Type, Refractory Diffuse Large B-Cell Lymphoma, Not Otherwise Specified, Refractory EBV-Positive Diffuse Large B-Cell Lymphoma, Not Otherwise Specified, Refractory Grade 3b Follicular Lymphoma, Refractory High Grade B-Cell Lymphoma With MYC and BCL2 Rearrangements, Refractory High Grade B-Cell Lymphoma, Not Otherwise Specified, Refractory Intravascular Large B-Cell Lymphoma, Refractory Primary Cutaneous Diffuse Large B-Cell Lymphoma, Leg Type, Refractory Primary Mediastinal Large B-Cell Lymphoma, Refractory T-Cell/Histiocyte-Rich Large B-Cell Lymphoma, Refractory Transformed Non-Hodgkin Lymphoma
- Interventions
- Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy, Chimeric Antigen Receptor T-Cell Therapy, Computed Tomography, Golcadomide, Leukapheresis, Positron Emission Tomography, Rituximab
- Procedure · Biological · Drug
- Lead sponsor
- Mayo Clinic
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 41 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2028
- U.S. locations
- 7
- States / cities
- Scottsdale, Arizona • Jacksonville, Florida • Albert Lea, Minnesota + 4 more
- Conditions
- Primary Immunodeficiency, Common Variable Hypogammaglobulinemia, X-linked Hypogammaglobulinemia, Hypogammaglobulinemia, Immunodeficiency With Hyper-IgM, Wiskott-Aldrich Syndrome
- Interventions
- Gammaplex (Intravenous immunoglobulin)
- Biological
- Lead sponsor
- Bio Products Laboratory
- Other
- Eligibility
- 3 Years and older
- Enrollment
- 50 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2007
- U.S. locations
- 7
- States / cities
- North Palm Beach, Florida • Atlanta, Georgia • Chicago, Illinois + 3 more
- Conditions
- Migraine
- Interventions
- Lu AG09222, Placebo
- Drug
- Lead sponsor
- H. Lundbeck A/S
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 52 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2022
- U.S. locations
- 1
- States / cities
- Glendale, California
- Conditions
- Prostatic Neoplasms, Prostate Cancer
- Interventions
- IL-12 gene
- Genetic
- Lead sponsor
- Baylor College of Medicine
- Other
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 4 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1998 – 2007
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Episodic Migraine
- Interventions
- Atogepant, Placebo
- Drug
- Lead sponsor
- Allergan
- Industry
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 910 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2020
- U.S. locations
- 138
- States / cities
- Chandler, Arizona • Glendale, Arizona • Phoenix, Arizona + 112 more
- Conditions
- Migraine
- Interventions
- Fremanezumab, Placebo
- Drug
- Lead sponsor
- Teva Branded Pharmaceutical Products R&D, Inc.
- Industry
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 875 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2017
- U.S. locations
- 178
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 77 more
- Conditions
- Brain and Central Nervous System Tumors
- Interventions
- fluorine F 18 fluorothymidine, positron emission tomography
- Other · Procedure
- Lead sponsor
- University of Washington
- Other
- Eligibility
- 18 Years to 120 Years
- Enrollment
- 12 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2006
- U.S. locations
- 1
- States / cities
- Seattle, Washington